NEET SS 2024 DrNB CLINICAL HAEMATOLOGY Paper3 Question Paper Available - Download Here with Solution PDF

a) Discuss the diagnostic criteria for Waldenström’s macroglobulinemia (WM).

b) Discuss the prognostic factors & prognostic system in WM.

c) Discuss the treatment response & outcomes based on these prognostic factors.

a) Describe the different imaging modalities used in multiple myeloma patients.

b) Discuss the sensitivity and specificity of these imaging modalities.

c) How are they optimally used in different scenarios in multiple myeloma?

a) Discuss the approach to diagnosis in a patient suspected of having Factor XIII deficiency?

b) What are the therapy options in this patient?

c) How will you care for a woman with Factor XIII deficiency who is planning for pregnancy?

a) Discuss management approach to an elderly, transplant ineligible multiple myeloma patient.

b) How do you decide treatment at first relapse in this patient?

c) Discuss treatment options for Lenalidomide-refractory or Bortezomib-refractory multiple myeloma patients.

a) A boy with hemophilia A with inhibitors comes to your center after a road traffic accident and requires urgent surgery. How will you manage surgery in this patient?

b) How will you manage and monitor the post-operative care in this patient?

c) What long term options are available for prophylaxis in this patient?

a) Describe the risk stratification of polycythemia vera (PV) patients.

b) Discuss the options for PV therapy in an elderly patient >60 years of age.

c) What are the evidence-based second-line therapies for PV patients?

a) Discuss the role of Azacytidine + Venetoclax (Aza+Ven) regimen in an elderly, frail patient with acute myeloid leukemia.

b) How will you decide treatment after first cycle of Aza+Ven therapy?

c) What are the options for this elderly patient if he relapses after 2 years while on Aza+Ven treatment?

a) In Philadelphia positive acute lymphoblastic leukemia (ALL), how is the choice of tyrosine kinase inhibitor (TKI) made?

b) Discuss the role of baseline tyrosine kinase domain mutation study in this scenario.

c) In an elderly patient with Philadelphia positive ALL, what are the chemotherapy-free treatment options?

a) Discuss the role of complement system in coagulation.

b) Mention new complement inhibitors used in treatment of paroxysmal nocturnal hemoglobinuria (PNH).

c) Discuss role of vaccination in PNH patients who are to be started on complement inhibitor therapies.

a) Discuss the diagnosis and prognosis of triple-negative myelofibrosis (TN-MF).

b) How does it differ from triple-negative essential thrombocytosis in prognosis?

c) Briefly discuss the genomic landscape of TN-MF.